Clinical Trial Update: Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating sequential infusion of CD19 and BCMA CAR-T cells for improving platelet transfusion refractoriness in acute leukemia in remission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia in Remission
• Platelet Transfusion Refractoriness

Drugs mentioned

• BCMA CAR-T cells (BCMA-targeted chimeric antigen receptor T cells)
• CD19 CAR T cells

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Platelet Transfusion Refractoriness, Acute Leukemia in Remission | Phase 1, Phase 2 | Status: UNKNOWN